Drug Profile
Research programme: anticancer therapies - Cynvec
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Cynvec
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Sep 2023 Preclinical development for anticancer therapeutics is ongoing in USA (Cynvec pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 11 Jul 2016 Preclinical trials in Cancer in USA (Parenteral)